[1] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中华肝脏病杂志, 2019, 27: 938-961.
[2] Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut, 2019, 68:2206-2213.
[3] Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut, 2019, 68:2105-2106.
[4] Kuo MT, Hu TH, Hung CH, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther, 2019, 49:218-228.
[5] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18:827-844.
[6] Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int, 2018, 38:84-89.
[7] Kim JH, Sinn DH, KangW, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66: 335-343.
[8] Shin JW, Jung SW, Lee SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. Am J Gastroenterol, 2018, 113: 998-1008.
[9] Ford N, Scourse R, Lemoine M, et al. Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun, 2018, 2:1160-1167.
[10] Tao YC, Wang ML, Zhang DM, et al. Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment. J Viral Hepat, 2020, 27:731-738.
[11] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68:672-681.
[12] Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut, 2014, 63:1325-1332.
[13] Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen negative chronic hepatitis B. Hepatology, 2018, 68:425-434.
[14] Chen CH, Hung CH, Hu TH, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol, 2015, 13:1984-1992.e1.
[15] Chen CH, Hung CH, Wang JH, et al. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect, 2018, 24:997-1003.
[16] Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 2021, 70:775-783.
[17] Fan R, Peng J, Xie Q, et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B. J Infect Dis, 2020, 222:611-618.
[18] Kao JH, Jeng WJ, Ning Q, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.Hepatol Int, 2021, 15:833-851.
[19] Liaw YF. Hepatitis B fare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat. Hepatology, 2021, 73(2): 843-852.
[20] Jeng WJ, Chang ML, Liaw YF. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. J Viral Hepat, 2019, 26:1019-1026.
[21] 张鹭,江建宁. HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物后复发的机制及再治疗策略进展. 肝脏, 2021, 26:477-479.
[22] Durantel D, Dousson CB, Lampertico P. Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? J Hepatol, 2021, 74:1011-1014.
[23] Higashi-Kuwata N, Hayashi S, Kumamoto H, et al. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. J Hepatol, 2021, 74:1075-1086.
[24] Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol, 2017, 66:275-281. |
